MicroRNA as Markers in Testicular Cancer

Last updated: August 5, 2022
Sponsor: Haukeland University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urologic Cancer

Germ Cell Tumors

Testicular Cancer

Treatment

N/A

Clinical Study ID

NCT04914026
2015/1475
  • Ages 18-70
  • Male

Study Summary

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with suspected testicular cancer, referred to orchiectomy.
  • Patients diagnosed with testicular germ cell cancer.
  • Age 18-70 years of age.
  • Must be able receive information and to consent.

Exclusion

Exclusion Criteria:

  • Other prior or concomitant malignancy (other than testicular cancer).
  • Other diseases or conditions that hinder the ability to receive information and toparticipate in follow-up procedures.

Study Design

Total Participants: 350
Study Start date:
December 31, 2016
Estimated Completion Date:
December 31, 2026

Study Description

The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of recurrence.

Connect with a study center

  • Haukeland University Hospital

    Bergen, 5021
    Norway

    Active - Recruiting

  • Haugesund Hospital

    Haugesund, 5528
    Norway

    Active - Recruiting

  • Oslo University Hospital

    Oslo, 0379
    Norway

    Site Not Available

  • University Hospital of North Norway

    Tromsø, 9038
    Norway

    Active - Recruiting

  • Sahlgrenska University Hospital

    Göteborg, 41345
    Sweden

    Site Not Available

  • Karolinska University Hospital

    Stockholm,
    Sweden

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.